Influenza Vaccines: Unmet Needs and Recent Developments

키워드

참고문헌 (98)

1. Hilleman MR, "Realities and enigmas of human viral influenza:pathogenesis, epidemiology and control", Vaccine, 20, pp.3068~3087 (2002)
2. McCullers JA, "Multiple genotypes ofinfluenza B virus circulated between 1979 and 2003", J Virol, 78, pp.12817~12828 (2004)
3. Smith W, "A virus obtainedfrom influenza patients", Lancet, 2, pp.66~68 (1933)
4. Francis T Jr, "A new type of virus from epidemic influenza", Science, 92, pp.405~408 (1940)
5. Cox NJ, "Influenza", Lancet, 354, pp.1277~1282 (1999)
6. Dawood FS, "Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation:a modelling study", Lancet Infect Dis, 12, pp.687~695 (2012)
7. Programme WHOGI, "Pandemic influenza preparednessand response: a WHO guidance document", World HealthOrganization, ~ (2009)
8. UK Influenza pandemic preparedness strategy, "Team DPIP", ~ (2011)
9. Kageyama S, "Pandemic influenza: a never-ending story", Yonago Acta Med, 54, pp.41~48 (2011)
10. Simonsen L, "GLaMOR Collaborating Teams. Global MortalityEstimates for the 2009 Influenza Pandemic from theGLaMOR Project : A Model ing Study", PLoS Med, 10, pp.e1001558~ (2013)
11. "Vaccines: Influenza"[URL]
12. Terebuh P, "Impact of influenza on youngchildren and the shaping of United States influenza vaccinepolicy", Pediatr Infect Dis J, 2(10), pp.S231~S235 (2003)
13. Centers for Disease Control and Prevention (CDC)., "Preventionand control of seasonal influenza with vaccines.Recommendations of the Advisory Committee on ImmunizationPractices--United States, 2013-2014", MMWR RecommRep, 62, pp.1~43 (2013)
14. Hannoun C, "The evolving history of influenza viruses andinfluenza vaccines", Expert Rev Vaccines, 12, pp.1085~1094 (2013)
15. Partridge J, "Global production capacity of seasonalinfluenza vaccine in 2011", Vaccine, 31, pp.728~731 (2013)
16. "WHO recommendations on the composition of influenzavirus vaccines"[URL]
17. Richard SA, "Evaluation of SouthernHemisphere influenza vaccine recommendations", Vaccine, 28, pp.2693~2699 (2010)
18. "World health organizationrecommendations for composition of influenza vaccines"[URL]
19. Nichol KL, "Efficacy and effectiveness of influenza vaccination", Vaccine, 26(4), pp.D17~D22 (2008)
20. DiazGranados CA, "Seasonal influenzavaccine efficacy and its determinants in children and nonelderlyadults: a systematic review with meta-analyses ofcontrolled trials", Vaccine, 31, pp.49~57 (2012)
21. Jefferson TO, "Vaccines for preventing influenza in healthyadults", Cochrane Database Syst Rev, pp.CD001269~ (2007)
22. Edwards KM, "A randomized controlled trial ofcold-adapted and inactivated vaccines for the preventionof influenza A disease", J Infect Dis, 169, pp.68~76 (1994)
23. Choi WS, "Case-control study of the effectivenessof the 2010-2011 seasonal influenza vaccinefor prevention of laboratory-confirmed influenza virus infectionin the Korean adult population", Clin Vaccine Immunol, 20, pp.877~881 (2013)
24. Beyer WE, "Supportfor policies to vaccinate elderly people against influenza", Vaccine, 31, pp.6030~6033 (2013)
25. Vu T, "A meta-analysis of effectivenessof influenza vaccine in persons aged 65 years andover living in the community", Vaccine, 20, pp.1831~1836 (2002)
26. Nichol KL, "The efficacy and cost effectiveness of vaccination againstinfluenza among elderly persons living in the community", N Engl J Med, 331, pp.778~784 (1994)
27. Carrat F, "Influenza vaccine: the challenge ofantigenic drift", Vaccine, 25, pp.6852~6862 (2007)
28. Nordin J, "Influenza vaccineeffectiveness in preventing hospitalizations anddeaths in persons 65 years or older in Minnesota, NewYork, and Oregon: data from 3 health plans", J Infect Dis, 184, pp.665~670 (2001)
29. Ambrose CS, "The role of nasalIgA in children vaccinated with live attenuated influenzavaccine", Vaccine, 30, pp.6794~6801 (2012)
30. Meadows M, "Nasal flu vaccine approved", FDA Consum, 37, pp.27~ (2003)
31. Ambrose CS, "The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults", Influenza Other Respir Viruses, 5, pp.67~75 (2011)
32. Longini IM, "Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control", Vaccine, 18, pp.1902~1909 (2000)
33. Belshe RB, "The efficacy of live attenuated, coldadapted, trivalent, intranasal influenzavirus vaccine in children", N Engl J Med, 338, pp.1405~1412 (1998)
34. Belshe RB, "Prevention of otitis media in children with live attenuated influenza vaccine given intranasally", Pediatr Infect Dis J, 19(5), pp.S66~S71 (2000)
35. Monto AS, "Comparative efficacy of inactivated and live attenuated influenza vaccines", N Engl J Med, 361, pp.1260~1267 (2009)
36. Prosser LA, "Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years", Arch Pediatr Adolesc Med, 165, pp.112~118 (2011)
37. Reed SG, "Key roles of adjuvants in modern vaccines", Nat Med, 19, pp.1597~1608 (2013)
38. Salk JE, "Direction of research on vaccination against influenza; new studies with immunologic adjuvants", Am J Public Health Nations Health, 41, pp.669~677 (1951)
39. Salk JE, "The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions", J Exp Med, 95, pp.429~447 (1952)
40. Anonymous, "Antibody responses and clinical reactionswith saline and oil adjuvant influenza virus vaccines", BrMed J, 2, pp.1229~1232 (1955)
41. Anonymous, "Antibody responses and clinical reactions with saline and oil adjuvant influenza virus vaccines", Br Med J, 2, pp.1229~1932 (1955)
42. Stuart-Harris CH, "Adjuvant influenza vaccines", Bull World Health Organ, 41, pp.617~621 (1969)
43. Davis DJ, "Epidemiologic studies on influenza in familial and general population groups. 1951-1956. III. Laboratory observations", Am J Hyg, 73, pp.138~147 (1961)
44. Tetsutani K, "Adjuvants in influenza vaccines", Vaccine, 30, pp.7658~7661 (2012)
45. Principi N, "Adjuvanted influenza vaccines", Hum Vaccin Immunother, 8, pp.59~66 (2012)
46. Lindblad EB, "Aluminium compounds for use in vaccines", Immunol Cell Biol, 82, pp.497~505 (2004)
47. Martin JT, "Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly", Biologicals, 25, pp.209~213 (1997)
48. Theodore F. Tsai, "Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults", Infection and Chemotherapy, 45(2), pp.159~174 (2013), 대한감염학회
49. Banzhoff A, "A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis", Gerontology, 49, pp.177~184 (2003)
50. Squarcione S, "Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects", Vaccine, 21, pp.1268~1274 (2003)
51. Podda A, "The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine", Vaccine, 19, pp.2673~2680 (2001)
52. Ansaldi F, "Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection", Vaccine, 27, pp.3345~3348 (2009)
53. Del Giudice G, "An MF59-adjuvanted inactivated influenza vaccine containing A", Panama, Fujian, pp.2002 than a subunit and a split influenza vaccine (1999), Vaccine[DOI]
54. Ansaldi F, "Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses", Vaccine, 26, pp.1525~1529 (2008)
55. Van Buynder PG, "The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly", Vaccine, 31, pp.6122~6128 (2013)
56. Mannino S, "Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy", Am J Epidemiol, 176, pp.527~533 (2012)
57. Song JY, "Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine", J Med Virol, 85, pp.1591~1597 (2013)
58. McElhaney JE, "Influence65 study group. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial", Lancet Infect Dis, 13, pp.485~496 (2013)
59. Koutsonanos DG, "Targeting the skin for microneedle delivery of influenza vaccine", Adv Exp Med Biol, 785, pp.121~132 (2013)
60. Nicolas JF, "Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice", Expert Rev Vaccines, 7, pp.1201~1214 (2008)
61. Durando P, "Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine", Hum Vaccin, 7, pp.29~40 (2011)
62. Belshe RB, "Serum antibody responses after intradermal vaccination against influenza", N Engl J Med, 351, pp.2286~2294 (2004)
63. Jo YM, "Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer", J Med Virol, 81, pp.722~727 (2009)
64. Beran J, "Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial", BMC Med, 7, pp.13~ (2009)
65. Arnou R, "Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study", Vaccine, 27, pp.7304~7312 (2009)
66. Marra F, "A meta-analysisof intradermal versus intramuscular influenza vaccines:immunogenicity and adverse events", InfluenzaOther Respir Viruses, 7, pp.584~603 (2013)
67. Marra F, "A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events", Influenza Other Respir Viruses, 7, pp.584~603 (2013)
68. Kis EE, "Devices for intradermal vac-vaccination", Vaccine, 30, pp.523~538 (2012)
69. Duggan ST, "Intanza 15 mug intradermal seasonalinfluenza vaccine in older adults (aged ≥60 years):profile report", BioDrugs, 24, pp.407~409 (2010)
70. Moro PL, "Adverse events after Fluzone®Intradermal vaccine reported to the Vaccine AdverseEvent Reporting System (VAERS), 2011-2013", Vaccine, 31, pp.4984~4987 (2013)
71. Falsey AR, "Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standarddose influenza vaccine in adults 65 years of age and older", J Infect Dis, 200, pp.172~180 (2009)
72. Tsang P, "Immunogenicityand safety of Fluzone® intradermal and high-doseinfluenza vaccines in older adults ≥65 years of age: A randomized,controlled, phase II trial", Vaccine (2013)
73. McKittrick N, "Improvedimmunogenicity with high-dose seasonal influenzavaccine in HIV-infected persons: a single-center, parallel,randomized trial", Ann Intern Med, 158, pp.19~26 (2013)
74. Sullivan SJ, "Advances in the vaccinationof the elderly against influenza: role of a high-dosevaccine", Expert Rev Vaccines, 9, pp.1127~1133 (2010)
75. DiazGranados CA, "High-dose trivalent influenza vaccinecompared to standard dose vaccine in elderly adults: safety,immunogenicity and relative efficacy during the 2009-2010 season", Vaccine, 31, pp.861~866 (2013)
76. Hess RD, "Regulatory, biosafetyand safety challenges for novel cells as substratesfor human vaccines", Vaccine, 30, pp.2715~2727 (2012)
77. Doroshenko A, "Trivalent MDCK cell culturederivedinfluenza vaccine Optaflu® (Novartis Vaccines)", Expert Rev Vaccines, 8, pp.679~688 (2009)
78. Reynales H, "A prospective observational safety study onMF59® adjuvanted cell culture-derived vaccine, Celtura®during the A", H1N1 (2009) influenza pandemic, 2012, pp.30, 6436~6443
79. Barrett PN, "Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenzavaccine: a multicentre, double-blind, randomised,placebo-controlled trial", Lancet, 377, pp.751~759 (2011)
80. Chan CY, "Preflucel®: a Vero-cell culture-derivedtrivalent influenza vaccine", Expert Rev Vaccines, 11, pp.759~773 (2012)
81. Vinnemeier CD, "Immunogenicity and safetyof an inactivated 2012", 2013 trivalent influenza vaccineproduced in mammalian cell culture (Optaflu®): An openlabel, uncontrolled study, 2013, ~
82. Frey S, "Clinical efficacy of cellculture-derived and egg-derived inactivated subunit influenzavaccines in heal thy adul ts", Cl in Infect Dis, 51, pp.997~1004 (2010)
83. Belshe RB, "The need for quadrivalent vaccine against seasonalinfluenza", Vaccine, 28(4), pp.D45~D53 (2010)
84. Ambrose CS, "The rationale for quadrivalent influenzavaccines", Hum Vaccin Immunother, 8, pp.81~88 (2012)
85. Kieninger D, "Immunogenicity, reactogenicity and safety of an inactivatedquadrivalent influenza vaccine candidate versus inactivatedtrivalent influenza vaccine: a phase III, randomizedtrial in adults aged ≥18 years", BMC Infect Dis, 13, pp.343~ (2013)
86. McKeage K, "Inactivated quadrivalent split-virus seasonalinfluenza vaccine (Fluarix® quadrivalent): a review of itsuse in the prevention of disease caused by influenza Aand B", Drugs, 73, pp.1587~1594 (2013)
87. Pepin S, "Safety and immunogenicity of a quadrivalent inactivatedinfluenza vaccine in adults", Vaccine, 31, pp.5572~5578 (2013)
88. Goldenberg MM, "Pharmaceutical approval update", PT, 38, pp.150~152 (2013)
89. Lambert LC, "Influenza vaccines for the future", NEngl J Med, 363, pp.2036~2044 (2010)
90. Yang LP, "Recombinant trivalent influenza vaccine (Flublok®): a review of its use in the prevention of seasonal influenzain adults", Drugs, 73, pp.1357~1366 (2013)
91. Treanor JJ, "Protective efficacy of a trivalentrecombinant hemagglutinin protein vaccine (Flu-Blok®) against influenza in healthy adults: a randomized,placebo-controlled trial", Vaccine, 29, pp.7733~7739 (2011)
92. Dormitzer PR, "New technologiesfor influenza vaccines", Hum Vaccin Immunother, 8, pp.45~58 (2012)
93. Ogunremi O, "Asingle electroporation delivery of a DNA vaccine containingthe hemagglutinin gene of Asian H5N1 avian influenzavirus generated a protective antibody response in chickensagainst a North American virus strain", Clin VaccineImmunol, 20, pp.491~500 (2013)
94. Li J, "Protective efficacy of an H5N1 DNA vaccine against challengewith a lethal H5N1 virus in quail", Avian Dis, 56(4), pp.937~939 (2012)
95. Ellebedy AH, "Influenza vaccines", Vaccine, 27(4), pp.D65~D68 (2009)
96. Shaw A, "New technologies for new influenza vaccines", Vaccine, 30, pp.4927~4933 (2012)
97. Pica N, "Toward a universal influenza virus vaccine:prospects and challenges", Annu Rev Med, 64, pp.189~202 (2013)
98. Goodman AG, "A human multi-epitope recombinantvaccinia virus as a universal T cell vaccine candidateagainst influenza virus", PLoS One, 6, pp.e25938~ (2011)

관련 논문AI추천